Stoke Therapeutics
Develops antisense medicines that restore protein expression in severe genetic diseases.
$31.62
After-hours close+0.01 (+0.03%)
At close$31.61(−3.01%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 121.36%Insiders 0.79%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 64.53M · Float 48.45M · 75.1% free float
Institutions13F, as of Jun 30, 2026
203 holders · 78.31M shares · 35 new positions · 111 increased · 57 reduced · 31 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.88M | 9.11% | +491.6K | Aug 7, 2026 |
| RTW Investments, LP | 5.62M | 8.72% | 0 | Aug 14, 2026 |
| FMR LLC | 5.31M | 8.23% | −70.6K | Aug 13, 2026 |
| LYNX1 Capital Management LP | 4.04M | 6.26% | −725.3K | Aug 13, 2026 |
| Redmile Group, LLC | 3.95M | 6.12% | −218.2K | Aug 14, 2026 |
| Wellington Management Group LLP | 3.52M | 5.45% | +423.6K | Aug 14, 2026 |
| Morgan Stanley | 3.45M | 5.35% | +29.5K | Aug 13, 2026 |
| Baker Bros. Advisors LP | 3.34M | 5.17% | 0 | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 9.90% | 5.94M | 13G | May 15, 2026 ↗ |
| FMR LLC | 9.80% | 5.60M | 13G | Feb 5, 2026 ↗ |
| Baker Bros. Advisors (GP) LLCincl. Felix J. Baker, Julian C. Baker +1 more | 8.30% | 4.37M | 13G | Nov 14, 2024 ↗ |
| Lynx1 Capital Management LP | 8.10% | 4.76M | 13G | May 18, 2026 ↗ |
| BlackRock, Inc. | 6.80% | 3.73M | 13G | Oct 17, 2025 ↗ |
| Redmile Group, LLC | 6.70% | 4.16M | 13G | May 15, 2026 ↗ |
| Morgan Stanley | 6.50% | 3.43M | 13G | Feb 3, 2025 ↗ |
| Baker Bros. Advisors LP | 5.80% | 3.34M | 13G | Feb 17, 2026 ↗ |
| The Toronto-Dominion Bank | 5.40% | 3.17M | 13G | May 15, 2026 ↗ |
| Wellington Management Group LLP | 5.20% | 3.10M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Skorpios Trust | 10 percent owner | 3.91M | 6.05% | Jun 6, 2025 |
| Adrian R. Krainer | director | 283.3K | 0.44% | Mar 12, 2026 |
| Edward M. MD Kaye | director | 124.6K | 0.19% | Aug 18, 2026 |
| Arthur Tzianabos | director, officer: Interim Executive Chair | 31.3K | 0.05% | Mar 12, 2026 |
| Barry Ticho | officer: CHIEF MEDICAL OFFICER | 25.7K | 0.04% | Aug 18, 2026 |
| Jonathan Allan | officer: GENERAL COUNSEL & CORP SEC | 21.2K | 0.03% | Aug 18, 2026 |
| Jason Hoitt | officer: Chief Patient Officer | 10.3K | 0.02% | Mar 19, 2026 |
| Thomas Leggett | officer: Chief Financial Officer | 10.2K | 0.02% | Mar 19, 2026 |
| Arthur A. Levin | director | 4.2K | 0.01% | Mar 17, 2026 |
3 ten-percent owners hold 8.12M shares by Form 4, outside the officers-and-directors figure above · 3 people have not refiled in the last 18 months (17.20M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Edward M. MD Kayedirector | Sale · 2 lots | 12,567 | $32.03 | 124,557 |
| Aug 18, 2026 | Barry Tichoofficer: CHIEF MEDICAL OFFICER | Sale · 2 lots | 4,767 | $32.03 | 25,655 |
| Aug 18, 2026 | Jonathan Allanofficer: GENERAL COUNSEL & CORP SEC | Sale · 2 lots | 2,861 | $32.03 | 21,225 |
| Aug 3, 2026 | Barry Tichoofficer: CHIEF MEDICAL OFFICER | Sale · 2 lots | 7,176 | $29.04 | 20,422 |
| Jul 1, 2026 | Barry Tichoofficer: CHIEF MEDICAL OFFICER | Sale · 2 lots | 7,228 | $32.66 | 27,598 |
| Jun 16, 2026 | Jonathan Allanofficer: GENERAL COUNSEL & CORP SEC | Sale | 1,457 | $29.95 | 18,086 |
| Jun 1, 2026 | Barry Tichoofficer: CHIEF MEDICAL OFFICER | Sale | 1,795 | $30.58 | 34,826 |
| May 1, 2026 | Barry Tichoofficer: CHIEF MEDICAL OFFICER | Sale | 2,243 | $32.79 | 36,621 |
| Apr 1, 2026 | Barry Tichoofficer: CHIEF MEDICAL OFFICER | Sale | 1,838 | $32.66 | 38,864 |
| Mar 20, 2026 | Jonathan Allanofficer: GENERAL COUNSEL & CORP SEC | Sale · 2 lots | 9,293 | $33.69 | 19,543 |
CongressHouse and Senate disclosures
Not reported.